Literature DB >> 19297275

The significance of Chlamydia trachomatis in urethritis and prostatitis - differences in therapeutic approach - Croatian experience.

Visnja Skerk1, L Markovinovic, S Zekan, J Jaksic, S Zidovec Lepej, A Markotic, Vedrana Skerk, V Radosevic, L Cvitkovic, J Begovac.   

Abstract

We examined a total of 1014 patients over 18 years of age; 252 with urethritis and 762 with chronic prostatitis syndrome. the mean age of patients with urethritis was 32.7 and with prostatitis syndrome 37.6 years. Clinical symptoms of urethritis were present from a few days to several months. in patients with chronic prostatitis syndrome, symptoms were present for at least 3 months. Chlamydia trachomatis alone was confirmed in 26 (10%) and in combination with Ureaplasma urealyticum in 6 (2%) patients with urethritis. in 171 (68%) patients with urethritis neither C. trachomatis nor U. urealyticum or Mycoplasma hominis were found. C. trachomatis alone was confirmed in 70 (9%), and in combination with other microorganisms in 7 (1%) patients with chronic prostatitis syndrome. in Croatia, the frequency of chronic chlamydial prostatitis has not significantly changed in the last 10 years, while the frequency of infections among adolescents decreased. the recommended regimen for acute chlamydial urethritis in Croatia is azithromycin 1.0 g as a single dose, and a total dose of 4-4.5 g azithromycin for chronic chlamydial prostatitis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19297275     DOI: 10.1179/joc.2009.21.1.63

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  1 in total

1.  In vitro susceptibility of urogenital Chlamydia trachomatis strains in a country with high azithromycin consumption rate.

Authors:  Suncanica Ljubin-Sternak; Tomislav Mestrovic; Tatjana Vilibic-Cavlek; Gordana Mlinaric-Galinovic; Mario Sviben; Alemka Markotic; Visnja Skerk
Journal:  Folia Microbiol (Praha)       Date:  2012-12-29       Impact factor: 2.099

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.